GlassScriptPhysician profile
Steven A Reyes
NPI 1144429366
$3,120.30
in general payments reported to CMS, 2019-2025
42 companies · $902 in 2025
The $902 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $314 · 2023: $823 · 2024: $1,081 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.51 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $269.84 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $256.35 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $180.78 | 2022-2025 | Airsupra, Farxiga, Andexxa |
| Novo Nordisk INC | $177.60 | 2022-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $175.62 | 2024 | Voquezna |
| Abbott Laboratories | $156.77 | 2022-2025 | Freestyle Libre 2, Mitraclip |
| Otsuka America Pharmaceutical, INC. | $142.03 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $138.97 | 2023-2025 | Ingrezza, Ongentys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.13 | 2025 | Caplyta |
| Pfizer INC. | $105.81 | 2023-2025 | |
| Amgen INC. | $88.39 | 2023-2024 | Repatha, Otezla, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $76.26 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.14 | 2024-2025 | Xifaxan |
| Ucb, INC. | $62.71 | 2022-2023 | Nayzilam |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $60.19 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $55.87 | 2022-2024 | Austedo Xr, Austedo |
| Alnylam Pharmaceuticals INC. | $54.82 | 2024 | Onpattro |
| Genzyme Corporation | $38.44 | 2025 | |
| Insmed, INC. | $36.83 | 2024-2025 | Brinsupri, Arikayce |
| Novartis Pharmaceuticals Corporation | $34.53 | 2022-2023 | |
| Renalytix Ai, INC. | $32.13 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $30.56 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $28.64 | 2023-2025 | Jardiance, Lyumjev, Baqsimi |
| Boston Scientific Corporation | $27.59 | 2024 | Watchman Access System |
| Nestle Healthcare Nutrition INC. | $25.55 | 2023 | |
| Viiv Healthcare Company | $24.90 | 2023 | Dovato |
| Scilex Pharmaceuticals INC. | $24.03 | 2024 | |
| Corcept Therapeutics | $23.19 | 2024 | Korlym |
| Ardelyx, INC. | $22.50 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.54 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.70 | 2025 | Cobenfy |
| Amneal Pharmaceuticals LLC | $19.58 | 2023 | Lyvispah |
| Merck Sharp & Dohme LLC | $19.35 | 2023 | Verquvo, Januvia, Belsomra |
| Smith+Nephew, INC. | $19.31 | 2025 | Collagenase Santyl |
| Lundbeck LLC | $17.57 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $17.40 | 2025 | Uptravi |
| Alkermes, INC. | $16.90 | 2023 | Aristada, Lybalvi |
| Shield Therapeutics INC | $15.02 | 2024 | |
| Dexcom, INC. | $14.83 | 2023 | Dexcom G6 Transmitter |
| Vivus LLC | $13.53 | 2022 | |
| Sumitomo Pharma America, INC. | $9.89 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.